Affordable Access

Publisher Website

Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer

Authors
Journal
The Breast
0960-9776
Publisher
Elsevier
Publication Date
Volume
18
Issue
1
Identifiers
DOI: 10.1016/j.breast.2008.09.007
Keywords
  • Bevacizumab
  • Breast Cancer
  • Trastuzumab
  • Resistance
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Antiangiogenic therapy is a valuable new approach in the treatment of breast cancer. Response rates ranging from 6.7% to 54% were reported using Bevacizumab (Avastin R), anti-vascular endothelial growth factor, with chemotherapy. We report the first case of a patient, with a highly vascular breast cancer that recurred locally while on treatment with paclitaxel and trastuzumab combination, but showed complete clinical and pathological regression upon the addition of bevacizumab therapy to the same combination.

There are no comments yet on this publication. Be the first to share your thoughts.